Research from Oxford has revealed a protein called galectin-1 as a key marker for disease progression and as a promising therapeutic target for patients with myeloproliferative neoplasms
Dr Zhe Huang talks about his work on investigating the proteomic profiles of prostate cancer, his OxCODE-funded trip to Boston and the story behind his early career
Cancer Research UK funds University of Oxford scientists to develop \u2018LynchVax\u2019, the UK\u2019s first vaccine aiming to prevent cancer in people with Lynch syndrome who have a much higher risk of developing several types of cancer.
Congratulations to OxCODE Operational Group Member Beth Psaila, who has been awarded a Senior Fellowship funded by Cancer Research UK in partnership with Rosetrees Trust.
Dr Defne Saatci and Professor Julia Hippisley-Cox aim to improve early diagnosis of cancers in this age group through earlier recognition of signs and symptoms.
Oxford University Hospitals (OUH) NHS Foundation Trust, North Bristol NHS Trust, and University Hospitals Coventry and Warwickshire (UHCW) NHS Trust are evaluating a new Artificial Intelligence (AI) diagnostic system that could help improve prostate cancer diagnosis.
GambitBio is developing an at-home lateral flow test to screen for the most common cancers, empowering people to take control of their health and reduce the number of cancer-related deaths. Cancer Research Horizons recently interviewed CEO, Tiffany Ma, who co-founded the venture while completing her DPhil at the University of Oxford.
Congratulations to Jingfei Cheng, Holly Eggington, Yi-Jhih Huang, Zhe Huang and Joshua Moore who have been awarded OxCODE funds to attend this year\u2019s major cancer prevention and early detection conferences.
OxCODE primary care researchers recently attended this year's Cancer Research UK Early Diagnosis Conference in Birmingham, which focused on the theme 'Driving Evidence into Practice'.
Proteins linked to cancer can start appearing in people\u2019s blood more than seven years before they\u2019re diagnosed. In the future, it\u2019s possible doctors could use these early warning signs to find and treat cancer much earlier than they\u2019re able to today.
The new method could help people with new-onset diabetes at high-risk of developing pancreatic cancer to be identified more accurately so that they can be monitored.
Oxford and UCL researchers seeking to create the world\u2019s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to \u00a31.7 million from Cancer Research UK and the CRIS Cancer Foundation.
The DeLIVER team will evaluate non-contrast-enhanced MRI and compare it to standard of care ultrasound in a cohort of patients under surveillance for liver cancer.
Professor Jason Davis and team have developed a new sensor to selectively and quantitatively measure p53 autoantibodies in the blood, levels of which are raised in a broad range of cancers.
A computer vision challenge was set to objectively quantify the generalisability of polyp detection and mapping algorithms, and challenge participants to innovate novel methods.
![](\"https://www.oxcode.ox.ac.uk/news/new-biomarker-and-therapeutic-target-identified-for-blood-cancers/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n